MCE products for research use only. We do not sell to patients.

L-DOPA

MCE China：L-DOPA

Brand：MedChemExpress (MCE)

Cat. No.HY-N0304

CAS：59-92-7

Synonyms：Levodopa; 3,4-Dihydroxyphenylalanine

Purity：99.98%

Storage：4°C, stored under nitrogen *The compound is unstable in solutions, freshly prepared is recommended.

Shipping：Room temperature in continental US; may vary elsewhere.

Description：L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.

In Vivo：L-DOPA can be used to create movement disorder models. In adult common marmosets, after oral administration of L-DOPA (20/5 mg/kg), the Tmax in plasma is 30 minutes, and the Tmax in striatal extracellular fluid (ECF) is 60-90 minutes. The mean Cmax of L-DOPA in plasma is 20.3 μM, while the mean Cmax in striatal ECF is 442.9 nM, representing about 2.2% of the plasma level[6]. .f12{ font-size: 12px; } .fwb{ font-weight: bold; } .lh22{ line-height: 22px;; } .lh23 { line-height: 23px; } .pl13{ padding-left: 13px;; } .part { margin-top: 18px; } .mold-first-tit { width: 100%; height: 44px; line-height: 44px; background: #F9F7FB; border-bottom: 1px solid #EBE4F6; padding-left: 16px; box-sizing: border-box; margin-bottom: 17px; } .mold-second-tit:before { content:""; width: 6px; height: 6px; display: inline-block; border-radius: 50%; background: rgba(255,102,0,0.4); margin-right: 12px; position: relative; top: -3px; } .lft-border { border-left: 1px dotted #EBE4F6; padding-right: 12px; margin-left: 3px; box-sizing: border-box; padding-bottom: 12px; } /* .part .dec:last-child { border-bottom: 0; } */ .dec { margin: 10px 15px 0; padding-bottom: 10px; border-bottom: 1px dashed #EBE4F6; } .btm-border { border-left: 1px dashed #EBE4F6; } .text-bg { margin-top: 10px; background: #FFFBF1; padding: 14px; border-bottom: 0; position: relative; } .text-note-bg { margin-top: 10px; background: #FFFDF7; padding: 12px; border-bottom: 0; position: relative; } .text-note { width: 51px; height: 20px; line-height: 20px; background: #FFE2AA; text-align: center; border-radius: 0 0 8px 0; position: absolute; top: 0; left: 0; } .text-note-dec { margin-top: 15px;; } Induction of dyskinesia model[5] Background L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia[5]. Specific Mmodeling Methods Mice: C57Bl/6 mice • male • 8 weeks (period: 21 days)Administration: 20 mg/kg • ip • once daily for 21 days Note (1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.(2) Injection volume is 10mL/kg body weight. Modeling Indicators Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion. Correlated Product(s): Oxidopamine hydrochloride (HY-B1081) Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A)

IC50 & Target：Human Endogenous Metabolite

Hot selling product：Benzetimide (hydrochloride)  | Ranirestat  | CGP77675  | 9-Phenanthrol  | DBCO-PEG4-triethoxysilane  | Roxithromycin-d7  | Physostigmine (hemisulfate)  | Sutimlimab  | Tusamitamab  | Cobimetinib (R-enantiomer)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.  [Content Brief]

[2]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.  [Content Brief]

[3]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.  [Content Brief]

[4]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.  [Content Brief]

[5]. M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194(1):66-75.  [Content Brief]

[6]. Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993(1-2):54-8.  [Content Brief]